$32.4 M

CLRB Mkt cap, 26-Nov-2020
Cellectar Biosciences Net income (Q2, 2020)-3.6 M
Cellectar Biosciences EBIT (Q2, 2020)-3.6 M
Cellectar Biosciences Cash, 30-Jun-202022.5 M
Cellectar Biosciences EV10.7 M

Cellectar Biosciences Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

R&D expense

3.6m5.1m6.9m6.0m5.2m4.8m9.5m6.8m9.0m

General and administrative expense

2.7m3.6m4.4m3.7m3.4m4.7m4.1m4.8m5.2m

Operating expense total

6.3m8.8m11.3m9.7m8.6m9.4m13.6m11.7m14.2m

EBIT

(7.0m)(8.8m)(12.4m)(9.9m)(8.8m)(9.4m)(13.6m)(13.3m)(14.2m)

Interest expense

430.0k8.3k9.3k446.3k841.07.9k16.6k29.7k42.7k

Income tax expense

933.6k

Net Income

(7.4m)(8.8m)(10.8m)(8.1m)(5.5m)(6.2m)(13.6m)(13.2m)(14.1m)

Cellectar Biosciences Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

5.5m4.7m2.4m9.4m3.9m11.4m10.0m13.3m10.6m

Prepaid Expenses

255.0k327.4k294.7k220.6k267.8k878.0k641.2k771.0k

Inventories

693.6k

Current Assets

5.8m5.1m2.8m9.7m4.2m12.2m10.9m14.0m11.4m

PP&E

3.0m2.6m2.4m2.0m1.7m244.7k543.3k435.1k

Goodwill

1.7m1.7m1.7m1.7m1.7m1.7m1.7m

Total Assets

10.6m11.5m6.8m13.4m7.6m15.3m12.9m15.1m12.3m

Accounts Payable

478.0k717.0k1.2m934.0k675.9k1.4m1.9m612.0k1.3m

Short-term debt

2.2k1.7k122.1k332.7k86.6k3.0k2.2k105.9k

Current Liabilities

503.6k732.7k4.5m2.2m5.7m1.6m2.1m1.6m2.8m

Long-term debt

4.1k450.0k450.0k791.2k94.6k2.2k421.6k

Non-Current Liabilities

578.5k587.1k593.2k489.0k243.5k151.8k2.2k171.0k421.6k

Total Debt

6.3k450.0k900.0k913.3k243.6k86.6k5.2k2.2k527.5k

Total Liabilities

5.1m2.7m5.9m1.8m2.1m1.8m3.2m

Common Stock

369.0464.0574.076.09.0167.047.094.0

Preferred Stock

Additional Paid-in Capital

41.0m50.4m52.8m69.9m66.3m83.5m94.1m108.3m119.6m

Retained Earnings

(59.2m)(64.6m)(70.8m)(84.3m)(97.6m)(111.7m)

Total Equity

9.5m10.2m1.7m10.7m1.6m13.5m10.8m13.3m9.1m

Debt to Equity Ratio

0 x0 x0.5 x0.1 x0.1 x0 x0 x0 x

Debt to Assets Ratio

0 x0 x0.1 x0.1 x0 x0 x0 x0 x

Financial Leverage

1.1 x1.1 x4 x1.2 x4.6 x1.1 x1.2 x1.1 x1.4 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

3.3m1.6m3.8m7.1m5.6m7.9m5.8m5.1m3.8m1.6m11.6m7.0m4.8m2.5m1.9m7.9m5.6m11.2m8.3m5.7m6.8m4.2m16.4m10.5m16.8m13.3m7.1m22.5m

Prepaid Expenses

53.1k303.6k183.3k139.0k336.0k191.8k147.4k329.4k212.3k335.0k290.4k171.0k118.6k445.3k281.4k162.2k437.6k893.2k969.6k970.2k770.0k780.6k686.0k604.7k1.3m1.5m771.3k593.6k

Current Assets

3.5m2.1m4.0m7.3m6.0m8.1m6.0m5.5m4.1m2.0m11.9m7.3m5.0m3.0m2.2m8.1m6.1m12.2m9.3m6.7m7.6m5.0m17.1m11.1m18.2m14.8m7.9m23.0m

PP&E

3.2m3.2m2.9m2.8m2.7m2.6m2.5m2.4m2.3m2.2m2.1m2.0m1.9m1.8m1.6m1.6m1.5m1.4m1.6m1.5m228.8k212.0k192.0k516.8k492.7k461.9k411.7k410.6k

Goodwill

1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m1.7m

Total Assets

8.4m7.0m8.6m11.9m10.4m14.3m12.1m9.6m8.0m5.9m15.7m10.9m8.6m6.5m5.6m11.4m9.3m15.3m12.6m9.9m9.6m7.0m19.5m12.5m19.1m15.7m8.7m23.9m

Accounts Payable

365.8k441.7k471.6k607.9k712.8k863.0k1.0m1.2m992.3k1.2m1.1m824.2k712.2k579.8k608.7k816.8k1.1m1.2m1.5m2.0m1.9m2.1m2.6m2.1m2.5m2.9m2.9m3.2m

Short-term debt

2.2k2.2k2.3k2.3k2.4k2.4k2.5k2.3k1.1k41.8k105.4k182.6k243.1k244.8k247.3k211.5k150.6k2.8k2.9k2.9k3.1k3.2k3.0k1.4k568.0109.3k112.7k

Current Liabilities

449.5k521.8k506.3k635.7k736.8k6.6m6.1m4.6m4.4m4.1m2.1m5.9m5.8m5.5m2.8m1.4m1.4m1.4m1.6m2.1m2.1m2.3m2.7m2.2m2.7m3.0m3.1m3.3m

Long-term debt

5.2k4.7k3.5k2.9k2.3k1.1k431.0450.0k4.2m4.2m357.9k279.5k218.2k156.5k32.2k6.6k6.0k4.5k3.8k3.3k1.4k568.0502.2k476.2k449.6k393.0k547.5k

Non-Current Liabilities

573.7k576.1k580.9k583.3k585.5k588.7k590.2k591.9k4.4m4.4m505.1k427.8k367.0k305.8k180.8k154.9k153.8k149.9k147.9k146.0k1.4k568.0502.2k476.2k449.6k393.0k547.5k

Total Debt

7.4k6.9k5.8k5.2k4.7k3.5k2.9k900.0k900.0k41.3k103.3k462.1k240.8k242.4k244.8k208.9k147.9k6.6k6.2k4.5k3.8k3.0k503.6k476.8k449.6k502.2k660.2k

Total Liabilities

1.1m1.2m1.3m7.2m6.7m5.2m8.8m8.4m2.6m6.3m6.2m5.8m3.0m1.5m1.6m1.5m1.7m2.3m2.1m2.3m2.7m2.7m3.2m3.4m3.4m3.9m

Common Stock

268.0268.0369.0431.0434.0574.0574.0574.0574.029.076.076.076.076.09.054.054.0135.0135.0135.0171.017.043.051.094.094.094.0254.0

Preferred Stock

637.0k1.1m

Additional Paid-in Capital

35.0m35.4m41.4m46.7m47.2m50.9m51.2m51.5m53.3m53.5m69.7m66.0m66.1m66.2m66.4m75.7m75.9m87.4m87.7m87.9m94.6m95.5m107.1m109.3m119.2m119.4m119.7m138.1m

Retained Earnings

(56.1m)(56.6m)(61.4m)(63.7m)(65.6m)(63.8m)(65.9m)(68.2m)(73.7m)(76.8m)(80.3m)(87.8m)(90.7m)(93.8m)(101.2m)(104.4m)(108.3m)(115.6m)(119.3m)

Total Equity

7.4m5.9m7.6m10.6m9.1m7.1m5.4m4.4m(727.3k)(2.5m)13.1m4.6m2.4m680.2k2.6m9.8m7.7m13.7m10.9m7.6m7.5m4.7m16.9m9.8m16.0m12.2m5.2m20.0m

Debt to Equity Ratio

0 x0 x0 x0 x0 x0 x0 x0.2 x-1.2 x0 x0 x0.1 x0.1 x0.4 x0.1 x0 x0 x0 x0 x0 x0 x0 x0.1 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0 x0 x0.1 x0.1 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x

Financial Leverage

1.1 x1.2 x1.1 x1.1 x1.1 x2 x2.2 x2.2 x-11.1 x-2.3 x1.2 x2.4 x3.6 x9.5 x2.2 x1.2 x1.2 x1.1 x1.2 x1.3 x1.3 x1.5 x1.2 x1.3 x1.2 x1.3 x1.7 x1.2 x

Cellectar Biosciences Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(3.6m)(5.5m)(2.4m)(4.6m)(6.6m)(3.5m)(5.5m)(6.8m)(2.9m)(5.0m)(5.5m)(2.3m)(4.6m)(6.4m)824.6k(1.3m)(3.6m)(2.9m)(6.0m)(9.5m)(3.5m)(6.4m)(9.4m)(3.6m)(6.8m)(10.7m)(4.0m)(7.6m)

Depreciation and Amortization

290.7k439.6k139.8k266.1k384.1k111.9k220.0k325.7k96.0k188.4k277.7k90.0k180.7k271.5k90.8k181.5k269.3k86.9k188.3k294.2k17.3k34.2k50.1k32.7k66.3k100.2k33.9k69.6k

Accounts Payable

(407.2k)(331.4k)(6.4k)129.8k234.8k146.0k304.5k440.3k(169.8k)33.3k(22.6k)(109.7k)(221.8k)(354.1k)(67.3k)140.8k411.5k(230.3k)49.9k602.8k16.0k225.9k703.8k511.3k984.2k1.3m277.5k543.2k

Cash From Operating Activities

(2.9m)(4.4m)(1.7m)(3.2m)(4.9m)(1.9m)(3.9m)(6.5m)(2.6m)(4.6m)(6.7m)(2.4m)(4.6m)(6.7m)(1.8m)(3.7m)(5.9m)(3.0m)(5.7m)(8.2m)(3.2m)(5.7m)(8.7m)(2.8m)(5.5m)(9.0m)(3.5m)(6.6m)

Purchases of PP&E

(23.1k)(112.2k)(15.1k)(29.1k)(37.1k)(93.0k)(93.0k)(135.0k)(15.2k)(15.2k)(17.4k)(25.5k)(33.7k)(39.8k)(4.2k)(5.3k)(66.3k)(320.5k)(346.7k)(1.4k)(1.4k)(1.4k)(6.2k)(15.7k)(18.8k)(10.6k)(45.1k)

Cash From Investing Activities

1.4m1.3m(15.1k)(29.1k)(37.1k)28.8k28.8k1.9m(15.2k)(15.2k)(17.4k)(25.5k)(33.7k)(39.8k)(4.2k)(5.3k)(66.3k)(320.5k)(346.7k)(1.4k)(1.4k)43.6k(6.2k)(15.7k)(18.8k)(10.6k)(45.1k)

Short-term Borrowings

(617.5k)(86.6k)(86.6k)(86.6k)

Long-term Borrowings

(675.7k)(675.7k)(544.0)(1.8k)(626.0)(1.3k)(1.7k)(1.2k)(2.1k)(62.0k)(61.1k)(122.5k)(184.1k)(655.0)(1.3k)(1.8k)(728.0)(1.5k)(2.2k)(811.0)(1.6k)(2.2k)

Cash From Financing Activities

4.2m4.1m(544.0)4.9m5.0m5.0m5.0m5.0m4.0m3.8m15.9m(1.2k)(2.1k)(191.7k)(131.2k)7.8m7.7m2.8m2.8m2.8m(728.0)(94.6k)15.0m(811.0)9.0m9.0m18.4m

Net Change in Cash

2.6m917.0k(1.7m)1.6m91.8k3.2m1.2m432.9k1.4m(792.4k)9.2m(2.4m)(4.6m)(7.0m)(1.9m)4.1m1.8m(206.2k)(3.1m)(5.8m)(3.2m)(5.8m)6.4m(2.8m)3.5m(9.0k)(3.5m)11.8m

Interest Paid

13.7k13.7k22.6k43.6k1.5k2.8k3.7k364.0364.0364.0880.0880.01.9k1.6k1.6k

Cellectar Biosciences Ratios

USDQ2, 2011

Financial Leverage

1.1 x